User login
Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.
Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; PFDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; PFDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.
Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.
Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source
Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.
Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; PFDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; PFDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.
Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.
Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source
Key clinical point: Levels of certain proteins found in the blood plasma affected the risk for development of psoriatic arthritis (PsA) and could serve as potential therapeutic targets for the condition.
Major finding: Apolipoprotein F increased the risk for PsA by 60% (odds ratio [OR] 1.69; PFDR < .001), whereas interleukin-10 reduced the risk for PsA by 40% (OR 0.60; PFDR = .034). Other proteins associated with an increased risk for PsA included tumor necrosis factor, V-type proton ATPase subunit G 2, receptor-type tyrosine protein phosphatase F, and septin-8.
Study details: This two-sample Mendelian randomization analysis included the data of 3537 patients with PsA and 262,844 control individuals without PsA from the FinnGen study and the data of 1837 unique plasma proteins from a genome-wide association study within the UK Biobank Pharma Proteomics Project.
Disclosures: This study was supported by the Natural Science Foundation of Guangxi Province and the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Zhao H, Zhou Y, Wang Z, Zhang X, Chen L, Hong Z. Plasma proteins and psoriatic arthritis: A proteome-wide Mendelian randomization study. Front Immunol. 15:1417564 (July 3). Doi: 10.3389/fimmu.2024.1417564 Source